Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > THe REaL INFeCTION

<< Previous

Bullboard Posts

Next >>

Comment by kindvalueon Apr 07, 2020 4:16pm

187 Views

Post# 30887967

RE:RE:THe REaL INFeCTION

No ICO doesnt own BERT
ICO out licensed so has no control of the asset
Yes Alexion must pay $6M milestone payment upon entering a phase 3 - probablity of that happening this year is even lower than Alexion developing a COVID drug - which is near zero

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec